It should be noted that while rh-APC and rh-TFPI were infused in a continuous fashion in clinical trials of sepsis [17,23,30,31,48,49], in the reviewed preclinical studies these anticoagulants were nebulized intermittently. The gene discussed is TFPI; the disease is Sepsis.